The study of miR-34a in cervical cancer began in 2009 when Wang et al. showed that cervical tumors and cervical cancer-derived cell lines containing oncogenic HPVs displayed reduced expression of tumor-suppressive miR-34a, attributed to the expression of the viral protein E6, which destabilizes the tumor suppressor p53, a known miR-34a transactivator (Wang et al., 2009). This evidence concerns the gene TP53 and neoplasm.